Derleme
BibTex RIS Kaynak Göster

Benzimidazollerin Antineoplastik Ajan Olarak Etkinliği

Yıl 2020, Cilt: 2 Sayı: 1, 29 - 35, 13.07.2020

Öz

Dünyada ve ülkemizde kanser en önemli sağlık sorunları arasında yer almaktadır. Hem insanlarda hem de hayvanlarda kanser tedavisinde kullanılan ilaçların ciddi yan etkilerinin olması ve pek çok kanser türünde halen istenilen tedavi başarısına ulaşılamaması, kanser ile mücadelede bilim insanlarını yeni stratejiler ve yeni tedavi yolları bulmaya zorlamaktadır. Bu sebeple halen ruhsatlı olarak kullanımda olan ilaçların anti-kanser etkilerinin araştırılması ve bu türden etkilerinin ortaya konulması hem yeni ilaç geliştirme sürecindeki zamandan ve hem de yüksek maliyeti azaltmak bakımından önem arz etmektedir. Yanı sıra halen kullanımda olan ruhsatlandırılmış ilaçların biyogüvenlikleri ve hastalar üzerindeki yan etkilerinin uzun yıllardır incelenmiş olması sebebiyle bu tür etken maddelerin anti-kanser ilacı olarak kullanılması durumunda konvansiyonel anti-kanser ilaçların hastalar üzerindeki ciddi yan etkilerinden kaçınılmış olması da kuvvetle muhtemeldir.

Kaynakça

  • Ammann R, Hoffmann A, Grimm F, Eckert J (1998) Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. Journal of Hepatology 29: 994-998.
  • Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ (2011) Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol 13: 974-982.
  • Barker H, Smyth R, Weissbach H, Toohey J, Ladd J, Volcani B (1960) Isolation and properties of crystalline cobamide coenzymes containing benzimidazole or 5, 6-dimethylbenzimidazole. Journal of Biological Chemistry 235: 480-488.
  • Bekhtı A, Pırotte J (1987) Cimetidine increases serum mebendazole concentrations. Br. J. clin. Pharmac. 24: 390-392.
  • Bogan J, Marriner S (1980) Analysis of benzimidazoles in body fluids by high-performance liquid chromatography. Journal of Pharmaceutical Sciences 69: 422-423.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68: 394-424.
  • Chıba Y, Kohri N, Isekı K, Mıyazaki K (1991) Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol. J Chemical pharmaceutical bulletin 39: 2158-2160.
  • Clément M-J, Rathinasamy K, Adjadj E, Toma F, Curmi PA, Panda D (2008) Benomyl and colchicine synergistically inhibit cell proliferation and mitosis: evidence of distinct binding sites for these agents in tubulin. J Biochemistry 47: 13016-13025.
  • Coyne CP, Jones T, Bear R (2018) Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicty in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. Journal of Clinical & Experimental Oncology 02: 10-122.
  • Dayan A (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. J Acta tropica 86: 141-159.
  • Deva S, Jameson M (2012) Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. J Cochrane Database of Systematic Reviews 8: 1-30.
  • Doudican N, Rodriguez A, Osman I, Orlow SJ (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 6: 1308-1315.
  • Doudican NA, Byron SA, Pollock PM, Orlow SJ (2013) XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs 24: 181-188.
  • Düwel D (1977) Fenbendazole. II. Biological properties and activity. J Pesticide Science 8: 550-555.
  • Gao P, Dang CV, Watson J (2008) Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science 47: 37-40.
  • Garcia-Rodriguez JJ, de la Torre-Iglesias PM, Vegas-Sanchez MC, Torrado-Duran S, Bolas-Fernandez F, Torrado-Santiago (2011) Changed crystallinity of mebendazole solid dispersion: improved anthelmintic activity. Int J Pharm 403: 23-28.
  • Gary AT, Kerl ME, Wiedmeyer CE, Turnquist SE, Cohn LA (2004) Bone marrow hypoplasia associated with fenbendazole administration in a dog. J Journal of the American Animal Hospital Association 40: 224-229.
  • Habib N, Aboulwafa OM (1982) Potential alkylating agents derived from benzimidazole and benzothiazole. J Journal of pharmaceutical sciences 71: 991-993.
  • Hirschberg E, Gellhorn A, Gump WS (1957) Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl) aminomethyl] benzimidazole, and of other 2-chloroethyl compounds. J Cancer research 17: 904-910.
  • Holden HE, Crider PA, Wahrenburg MG (1980) Mitotic arrest by benzimidazole analogs in human lymphocyte cultures. J Environmental mutagenesis 2: 67-73.
  • Ibrahim E-SA, Omar A-MM, Khalil M (1980) Novel potential anticancer agents derived from benzimidazole. J Journal of pharmaceutical sciences 69: 1348-1350.
  • Kumar,(2013) Neoplazi, In: Robins Temel Patoloji 9ed. Nobel Tıp Kitabevleri, İstanbul,pp 161-190.
  • Lanusse CE, Prichard RK (1993) Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Methabolism Rewievs 25: 235-279.
  • Laryea D, Gullbo J, Isaksson A, Larsson R, Nygren P (2010) Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells. J Anti-Cancer Drugs 21: 33-42.
  • Liu CS, Zhang HB, Jiang B, Yao JM, Tao Y, Xue J, Wen AD (2012) Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. Parasitol Res 111: 1205-1211.
  • Martarelli D, Pompei P, Baldi C,Mazzoni G (2008) Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 61: 809-817.
  • McKellar Q, Scott E (1990) The benzimidazole anthelmintic agents‐a review. Journal of veterinary pharmacology therapeutics 13: 223-247.
  • Mukhopadhyay T, Sasaki J-i, Ramesh R, Roth JA (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clinical cancer research 8: 2963-2969.
  • Nygren P, Fryknas M, Agerup B, Larsson R (2013) Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol 139: 2133-2140.
  • Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP (2014) Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience 8: 443.
  • Pinto LC, Soares BM, Pinheiro JdJV, Riggins GJ, Assumpcao PP, Burbano RMR, Montenegro RC (2015) The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. J Toxicology in vitro 29: 2038-2044.
  • Reute S, Jensen B, Buttenschoen K, Kratzer W, Kern P (2000) Bendimidazole trethment of alveollar echinecococosis. The journal of biological chemistry 46: 451-456.
  • Sanchez S, Sallovitz J, Savio E, Mckellar Q, Lanusse C (2000) Comparative availability of two oral dosage forms of albendazole in dogs. J The Veterinary Journal 160: 153-156.
  • Sasaki J-i, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T (2002) The Anthelmintic Drug Mebendazole Induces Mitotic Arrest and Apoptosis by Depolymerizing Tubulin in Non-Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics 1: 1201-1209.
  • Schmıt JM (2013) in vitro anti-cancer effects of benzimidazoles on the canine osteosarcoma d17 cell line. Master of Science, University of Illinois.
  • Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
  • Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, Fine N, Simpson CD, Sharmeen S, Rottapel R, Schimmer AD (2010) The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115: 4824-4833.
  • Spasov A, Smirnova L, Iezhitsa I, Sergeeva S, Ozerov A (2002) Pharmacokinetics of benzimidazole derivatives. J Voprosy meditsinskoi khimii 48: 233-258.
  • Van den Bossche H, Rochette F, Hörig C (1982) Mebendazole and related anthelmintics, In: Advances in Pharmacology. Elsevier,pp 67-128.
  • Velık J, Baliharova V, Fink-Gremmels J, Bull S, Lamka J, Skálová L (2004) Benzimidazole drugs and modulation of biotransformation enzymes. J Research in veterinary science 76: 95-108.
  • WHO(2020) Cancer. https://www.who.int/health-topics/cancer#tab=tab_1 (erişim tarhi 03.01.2020).
  • Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern pathology 20: 416.
Yıl 2020, Cilt: 2 Sayı: 1, 29 - 35, 13.07.2020

Öz

Kaynakça

  • Ammann R, Hoffmann A, Grimm F, Eckert J (1998) Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. Journal of Hepatology 29: 994-998.
  • Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ (2011) Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol 13: 974-982.
  • Barker H, Smyth R, Weissbach H, Toohey J, Ladd J, Volcani B (1960) Isolation and properties of crystalline cobamide coenzymes containing benzimidazole or 5, 6-dimethylbenzimidazole. Journal of Biological Chemistry 235: 480-488.
  • Bekhtı A, Pırotte J (1987) Cimetidine increases serum mebendazole concentrations. Br. J. clin. Pharmac. 24: 390-392.
  • Bogan J, Marriner S (1980) Analysis of benzimidazoles in body fluids by high-performance liquid chromatography. Journal of Pharmaceutical Sciences 69: 422-423.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68: 394-424.
  • Chıba Y, Kohri N, Isekı K, Mıyazaki K (1991) Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol. J Chemical pharmaceutical bulletin 39: 2158-2160.
  • Clément M-J, Rathinasamy K, Adjadj E, Toma F, Curmi PA, Panda D (2008) Benomyl and colchicine synergistically inhibit cell proliferation and mitosis: evidence of distinct binding sites for these agents in tubulin. J Biochemistry 47: 13016-13025.
  • Coyne CP, Jones T, Bear R (2018) Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicty in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. Journal of Clinical & Experimental Oncology 02: 10-122.
  • Dayan A (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. J Acta tropica 86: 141-159.
  • Deva S, Jameson M (2012) Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. J Cochrane Database of Systematic Reviews 8: 1-30.
  • Doudican N, Rodriguez A, Osman I, Orlow SJ (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 6: 1308-1315.
  • Doudican NA, Byron SA, Pollock PM, Orlow SJ (2013) XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs 24: 181-188.
  • Düwel D (1977) Fenbendazole. II. Biological properties and activity. J Pesticide Science 8: 550-555.
  • Gao P, Dang CV, Watson J (2008) Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science 47: 37-40.
  • Garcia-Rodriguez JJ, de la Torre-Iglesias PM, Vegas-Sanchez MC, Torrado-Duran S, Bolas-Fernandez F, Torrado-Santiago (2011) Changed crystallinity of mebendazole solid dispersion: improved anthelmintic activity. Int J Pharm 403: 23-28.
  • Gary AT, Kerl ME, Wiedmeyer CE, Turnquist SE, Cohn LA (2004) Bone marrow hypoplasia associated with fenbendazole administration in a dog. J Journal of the American Animal Hospital Association 40: 224-229.
  • Habib N, Aboulwafa OM (1982) Potential alkylating agents derived from benzimidazole and benzothiazole. J Journal of pharmaceutical sciences 71: 991-993.
  • Hirschberg E, Gellhorn A, Gump WS (1957) Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl) aminomethyl] benzimidazole, and of other 2-chloroethyl compounds. J Cancer research 17: 904-910.
  • Holden HE, Crider PA, Wahrenburg MG (1980) Mitotic arrest by benzimidazole analogs in human lymphocyte cultures. J Environmental mutagenesis 2: 67-73.
  • Ibrahim E-SA, Omar A-MM, Khalil M (1980) Novel potential anticancer agents derived from benzimidazole. J Journal of pharmaceutical sciences 69: 1348-1350.
  • Kumar,(2013) Neoplazi, In: Robins Temel Patoloji 9ed. Nobel Tıp Kitabevleri, İstanbul,pp 161-190.
  • Lanusse CE, Prichard RK (1993) Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Methabolism Rewievs 25: 235-279.
  • Laryea D, Gullbo J, Isaksson A, Larsson R, Nygren P (2010) Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells. J Anti-Cancer Drugs 21: 33-42.
  • Liu CS, Zhang HB, Jiang B, Yao JM, Tao Y, Xue J, Wen AD (2012) Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. Parasitol Res 111: 1205-1211.
  • Martarelli D, Pompei P, Baldi C,Mazzoni G (2008) Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 61: 809-817.
  • McKellar Q, Scott E (1990) The benzimidazole anthelmintic agents‐a review. Journal of veterinary pharmacology therapeutics 13: 223-247.
  • Mukhopadhyay T, Sasaki J-i, Ramesh R, Roth JA (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clinical cancer research 8: 2963-2969.
  • Nygren P, Fryknas M, Agerup B, Larsson R (2013) Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol 139: 2133-2140.
  • Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP (2014) Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience 8: 443.
  • Pinto LC, Soares BM, Pinheiro JdJV, Riggins GJ, Assumpcao PP, Burbano RMR, Montenegro RC (2015) The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. J Toxicology in vitro 29: 2038-2044.
  • Reute S, Jensen B, Buttenschoen K, Kratzer W, Kern P (2000) Bendimidazole trethment of alveollar echinecococosis. The journal of biological chemistry 46: 451-456.
  • Sanchez S, Sallovitz J, Savio E, Mckellar Q, Lanusse C (2000) Comparative availability of two oral dosage forms of albendazole in dogs. J The Veterinary Journal 160: 153-156.
  • Sasaki J-i, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T (2002) The Anthelmintic Drug Mebendazole Induces Mitotic Arrest and Apoptosis by Depolymerizing Tubulin in Non-Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics 1: 1201-1209.
  • Schmıt JM (2013) in vitro anti-cancer effects of benzimidazoles on the canine osteosarcoma d17 cell line. Master of Science, University of Illinois.
  • Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
  • Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, Fine N, Simpson CD, Sharmeen S, Rottapel R, Schimmer AD (2010) The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115: 4824-4833.
  • Spasov A, Smirnova L, Iezhitsa I, Sergeeva S, Ozerov A (2002) Pharmacokinetics of benzimidazole derivatives. J Voprosy meditsinskoi khimii 48: 233-258.
  • Van den Bossche H, Rochette F, Hörig C (1982) Mebendazole and related anthelmintics, In: Advances in Pharmacology. Elsevier,pp 67-128.
  • Velık J, Baliharova V, Fink-Gremmels J, Bull S, Lamka J, Skálová L (2004) Benzimidazole drugs and modulation of biotransformation enzymes. J Research in veterinary science 76: 95-108.
  • WHO(2020) Cancer. https://www.who.int/health-topics/cancer#tab=tab_1 (erişim tarhi 03.01.2020).
  • Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern pathology 20: 416.
Toplam 42 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Veteriner Cerrahi
Bölüm Derleme
Yazarlar

Mahmut Şahin 0000-0003-3765-748X

Yayımlanma Tarihi 13 Temmuz 2020
Yayımlandığı Sayı Yıl 2020Cilt: 2 Sayı: 1

Kaynak Göster

APA Şahin, M. (2020). Benzimidazollerin Antineoplastik Ajan Olarak Etkinliği. Turkish Veterinary Journal, 2(1), 29-35.